Beta Bionics (NASDAQ:BBNX) Now Covered by William Blair
William Blair has initiated coverage of Beta Bionics (NASDAQ:BBNX) with a "market perform" rating, contributing to the stock's "Moderate Buy" consensus and an average price target of $20.10. The company recently reported better-than-expected quarterly revenue of $32.01 million and an adjusted loss of $0.53 per share. Institutional investors like BlackRock and Vanguard have increased their stakes, while insiders have sold a total of 36,355 shares over the past 90 days.
William Blair initiates Beta Bionics stock rating at Market Perform
William Blair has initiated coverage on Beta Bionics (NASDAQ:BBNX) with a Market Perform rating, citing the company's unique AID algorithm and strong revenue growth. While the stock is currently trading above its Fair Value according to InvestingPro, Beta Bionics holds more cash than debt and plans to enter the patch pump market in 2027. Despite a recent earnings miss with a larger-than-expected loss per share, the company maintained its full-year outlook.
William Blair initiates Beta Bionics stock rating at Market Perform By Investing.com
William Blair has initiated coverage of Beta Bionics (NASDAQ:BBNX) with a Market Perform rating, citing the company's iLet insulin pump's unique AID algorithm and strong revenue growth. Despite a recent earnings miss, Beta Bionics maintained its full-year outlook, and analysts highlighted its strong financial position with more cash than debt and upcoming entry into the patch pump market in 2027.
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
Johnson Fistel, PLLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) for potential securities law violations due to allegedly false or misleading statements regarding the Company's growth trends, new patient starts, and business outlook. The investigation follows Beta Bionics' disclosure of slower new patient start growth for Q4 2025, which fell below analyst expectations despite reported year-over-year growth. Investors who suffered losses after purchasing Beta Bionics securities are encouraged to contact Johnson Fistel to discuss their legal rights.
Farallon group discloses 595,000-share Beta Bionics (BBNX) stake in 13G/A
Farallon Capital Management, L.L.C. and its affiliated funds have disclosed a beneficial ownership of 595,000 shares, representing 1.3% of Beta Bionics, Inc. (BBNX) common stock as of June 30, 2026. This stake was reported in a SCHEDULE 13G/A SEC filing, indicating shared voting and dispositive power over these shares. The filing lists various Farallon entities and key individuals as reporting persons.
BofA Securities Maintains Beta Bionics(BBNX.US) With Hold Rating, Raises Target Price to $18
BofA Securities has maintained its Hold rating on Beta Bionics (BBNX.US) and increased its target price for the company's stock to $18. This adjustment reflects BofA's updated outlook for Beta Bionics.
Beta Bionics, Inc. Stock 12‑Month Price Target Raised to $20.31, Implies 24% Upside
Beta Bionics, Inc. (BBNX) has seen its average 12-month price target raised from $20.08 to $20.31 by 11 analysts, with forecasts ranging from $14 to $30.4 per share. This new target implies a potential upside of approximately 24% from its August 10 closing price. The consensus rating for BBNX remains a "Buy," with 8 analysts recommending a buy and 3 recommending a hold.
Beta Bionics (NASDAQ:BBNX) Shares Up 13.7% - Should You Buy?
Beta Bionics (NASDAQ:BBNX) saw its shares surge by 13.7% to $16.05, trading above its 50-day and 200-day moving averages, though its high beta of 3.13 indicates significant volatility. Analysts hold a "Moderate Buy" consensus with a $20.10 price target, despite one firm issuing a "sell" rating and wide target range. The company beat EPS estimates but remains unprofitable with negative margins and projected full-year EPS of -$2.10, while insiders have sold shares, and institutional investors have adjusted their holdings.
Lazard Asset Management LLC Buys New Holdings in Beta Bionics, Inc. $BBNX
Lazard Asset Management LLC has acquired a new stake of 71,905 shares in Beta Bionics (NASDAQ:BBNX), valued at approximately $720,000, representing 0.16% ownership. Other institutional investors also established or increased positions in the company. Beta Bionics shares recently traded down 4.5% at $13.91, with a market capitalization of around $626 million, and analysts hold a "Moderate Buy" consensus with an average price target of $20.10, despite recent insider share sales.
Perceptive Advisors LLC Buys 240,000 Shares of Beta Bionics, Inc. $BBNX
Perceptive Advisors LLC significantly increased its stake in Beta Bionics, Inc. (NASDAQ:BBNX) by 39.8% in the first quarter, purchasing an additional 240,000 shares to bring its total holdings to 842,944 shares valued at approximately $8.45 million. The company has a "Moderate Buy" consensus rating from analysts with a target price of $20.10, despite recent insider stock sales and the stock trading well below its 52-week high. Beta Bionics reported quarterly revenue of $32.01 million and an adjusted loss of $0.53 per share, outperforming analyst expectations.
Beta Bionics (Nasdaq: BBNX) lifts Q2 sales to $32M amid ongoing losses
Beta Bionics (Nasdaq: BBNX) reported a significant increase in Q2 2026 net sales to $32.0 million, up from $23.2 million a year prior, primarily driven by its iLet insulin delivery device and single-use consumables. Despite this growth, the company continues to experience substantial losses, with a six-month net loss of $45.3 million due to high operating expenses, including research and development, sales and marketing, and administrative costs. The company is strategically shifting sales towards the pharmacy benefit plan (PBP) channel and investing in next-generation products like the Mint tubeless patch pump, even as it addresses an FDA Warning Letter from January 2026 concerning quality system deficiencies.
Beta Bionics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BBNX) 2026-07-31
Beta Bionics, Inc. (BBNX) published its Q2 2026 earnings call presentation, reporting an EPS of -$0.36, beating estimates by $0.20, and revenue of $32.01M, surpassing expectations by $533.03K with a 37.76% year-over-year increase. The slide deck was released in conjunction with the company's earnings call.
A Quick Look at Today's Ratings for Beta Bionics(BBNX.US), With a Forecast Between $15.5 to $30.4
This article provides an overview of recent analyst ratings for Beta Bionics (BBNX.US), highlighting a forecast range for its stock price between $15.5 and $30.4. It appears to be a summary of current market sentiment regarding the company's valuation.
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
Johnson Fistel, PLLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) for potential securities law violations after the company disclosed slower new patient start growth for Q4 2025, which fell below analyst expectations and showed significant deceleration from the previous quarter. The law firm is seeking investors who suffered losses to join their investigation into whether Beta Bionics made false or misleading statements regarding its growth trends and business outlook.
Law firm probes Beta Bionics for possible misleading growth claims affecting investors
Johnson Fistel, PLLP is investigating Beta Bionics for potential securities law violations due to allegedly misleading statements about its growth and new patient starts. This probe was triggered by Beta Bionics' disclosure of significantly slower growth in new patient starts for Q4 2025, which did not meet analyst expectations. The investigation aims to address the impact on investors who may have suffered losses based on the company's public statements.
Beta Bionics Q2 Earnings Call Highlights
Beta Bionics reported strong Q2 2026 financial results, with net sales up 38% year-over-year to $32 million, driven by its iLet insulin-delivery system. The company reaffirmed its 2026 revenue guidance, raised its gross-margin outlook, and provided updates on its Mint patch pump development, Type 2 diabetes indication expansion, and bi-hormonal programs. Beta Bionics also noted significant progress in addressing an FDA warning letter.
Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
Beta Bionics reported net sales of $32.0 million for the second quarter of 2026, marking a 38% increase year-over-year, with strong growth in its Pharmacy Benefit Plan channel. The company initiated a pivotal trial for its iLet device in type 2 diabetes and updated its full year 2026 guidance, maintaining revenue estimates while slightly narrowing its gross margin forecast. Beta Bionics also provided updates on its Mint patch pump and its bihormonal system in development, alongside emphasizing its commitment to data transparency with a new public real-world data dashboard.
Beta Bionics, Inc. (BBNX) Reports Q2 Loss, Tops Revenue Estimates
Beta Bionics, Inc. (BBNX) reported a Q2 loss of $0.53 per share, exceeding the Zacks Consensus Estimate of a $0.62 loss, and revenues of $32.01 million, surpassing estimates by 2.07%. Despite outperforming earnings and revenue expectations, the company's shares have declined by 48.2% year-to-date, and its current Zacks Rank is #4 (Sell), suggesting a potential underperformance in the near future. The Medical - Instruments industry, to which Beta Bionics belongs, is also in the bottom 39% of Zacks industries.
Press Release: Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
Beta Bionics has announced its second-quarter 2026 financial results, which include updates to its full-year 2026 guidance. This press release provides key financial figures and operational highlights for the period. The company shared important business updates and its outlook for the remainder of the fiscal year.
BETA BIONICS INC : UBS CUTS TARGET PRICE TO $22 FROM $24
UBS has lowered its target price for Beta Bionics Inc. (BBNX.O) from $24 to $22. This update was reported by Reuters on July 28, 2026. This article does not provide a detailed analysis behind the target price cut but simply states the change.
Here's Why We're Not Too Worried About Beta Bionics' (NASDAQ:BBNX) Cash Burn Situation
Beta Bionics (NASDAQ:BBNX) has a solid cash runway of about 3.3 years, holding US$200 million in cash against an annual burn of US$61 million. Despite a slight increase in cash burn, the company's strong revenue growth of 58% and low cash burn relative to its market capitalization suggest it is in a decent financial position and could easily raise more capital if needed. This indicates that the company is managing its cash effectively and is on track to meet its medium-term financial needs.
UBS Adjusts Price Target on Beta Bionics to $22 From $24, Maintains Buy Rating
UBS has adjusted its price target for Beta Bionics (BBNX) to $22, down from $24, while maintaining a Buy rating on the stock. This update reflects a revised valuation perspective for the medical device company, which specializes in insulin delivery systems for people with diabetes. Beta Bionics is known for its iLet Bionic Pancreas and is developing a patch pump and a bihormonal configuration of the iLet.
Here's Why We're Not Too Worried About Beta Bionics' (NASDAQ:BBNX) Cash Burn Situation
Beta Bionics (NASDAQ:BBNX) is increasing its cash burn, but its strong revenue growth of 58% and a cash runway of 3.3 years alleviate concerns. The company holds US$200m in cash with no debt, and its cash burn of US$61m last year represents a low 8.7% of its US$706m market capitalization, suggesting it could easily raise more capital if needed. Overall, the company's financial position is deemed relatively comfortable for meeting its medium-term needs.
Beta Bionics, Inc. Revenue Breakdown – NASDAQ:BBNX
Beta Bionics, Inc. (NASDAQ: BBNX) reported total revenue of $100.25 million USD last year. The majority of this revenue, $75.82 million USD, came from its Durable Medical Equipment segment, a significant increase from the previous year's $58.81 million USD. All of the company's revenue was generated within the United States.
Beta Bionics Inc (BBNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Beta Bionics Inc (BBNX) based on business segments for FY2025. The company's revenue streams are primarily from DME channel sales of iLet and single-use products, and PBP channel sales of single-use products and iLet. The data indicates that the DME channel for iLet products contributes the largest proportion of the company's revenue.
BBNX|Beta Bionics Inc|Price:16.097|Chg%:+0.247
This article provides a comprehensive stock analysis of Beta Bionics Inc (BBNX) using the TradingKey Stock Score. It highlights strong fundamentals, significant growth potential, and a fairly valued assessment, with institutional ownership being very high. The company specializes in medical devices for insulin-requiring diabetes patients, particularly the iLet Bionic Pancreas, and analysts have rated it as a "Buy" with a target price of 20.18.
Beta Bionics (BBNX) Stock Fair Value Falls As Medtech Reset Tempers iLet And Mint Optimism
The fair value estimate for Beta Bionics (BBNX) has decreased from US$31.30 to US$19.80 per share, aligning more closely with current analyst price targets. This adjustment reflects a balance between continued optimism for their iLet product and planned Mint launch, and broader medtech sector valuation resets and headwinds. Analysts have varying price targets, from US$13 to US$22, indicating both product progress and market-wide pressures.
Beta Bionics Inc (BBNX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides details on Beta Bionics Inc (BBNX) stock, focusing on its dividend and stock split history. It indicates that the company has distributed $0.00 in dividends over the past five years, with no dividend data currently available. The page also presents current stock performance metrics and market capitalization for BBNX.
Beta Bionics Inc (BBNX) Institutional Confidence
Beta Bionics Inc (BBNX) has an institutional shareholding score of 10.00, ranking it 1st in the Healthcare Equipment & Supplies industry. Institutional shareholding proportion increased by 4.12% quarter-over-quarter to 110.51%. Frank Sands is the largest institutional shareholder, holding 3.08 million shares, representing 8.01% of shares outstanding despite a 1.35% decrease in holdings.
Beta Bionics (BBNX) sees 6.9% stake reported by Divisadero Street group
A Schedule 13G SEC filing reveals that Divisadero Street Capital Management, LP, along with William Zolezzi and related entities, has acquired a significant beneficial ownership of 3,072,985 shares in Beta Bionics, Inc. (BBNX), representing 6.9% of the common stock. This filing indicates shared voting and dispositive power over these shares, with direct ownership by advisory clients of Divisadero Street Capital Management, LP. The involved parties disclaim beneficial ownership beyond their pecuniary interest.
BBNX|Beta Bionics Inc|Price:15.860|Chg%:-0.270
This article provides a detailed financial overview of Beta Bionics Inc. (BBNX), including its market performance, financial statements, and key financial indicators. It highlights the company's earnings, revenue, EPS, and various balance sheet and cash flow metrics, alongside an analyst rating of "BUY." The content also includes an FAQ section summarizing the company's financial results from its FY2025 earnings report.
BBNX|Beta Bionics Inc|Price:16.330|Chg%:+0.200
Beta Bionics Inc. (BBNX) is a commercial-stage medical device company focused on solutions for insulin-requiring diabetes patients, particularly with its iLet Bionic Pancreas. The company exhibits strong fundamentals with significant revenue growth and high institutional ownership, though its stock performance has been mixed recently. Analysts have a "Buy" rating with a target price of $20.18, suggesting moderate upside potential.
Beta Bionics (BBNX) price target decreased by 11.15% to 20.99
This article reports that Beta Bionics (BBNX) has experienced an 11.15% decrease in its price target, bringing it down to $20.99. No further details are provided regarding the reasons behind this adjustment or the analyst responsible. The content is very brief and lacks additional information.
Beta Bionics (BBNX) price target decreased by 11.15% to 20.99
This article reports that the price target for Beta Bionics (BBNX) has been decreased by 11.15%, setting the new target at $20.99. The adjustment indicates a revised outlook for the company's valuation.
BBNX Maintained by Goldman Sachs -- Price Target Raised to $19.0
Goldman Sachs has maintained its 'Buy' rating for Beta Bionics (BBNX) and raised the price target to $19.00 from $17.00, reflecting optimism about the company's growth, particularly its iLet Bionic Pancreas product. Despite this positive analyst outlook, BBNX has a low GF Score™ of 10/100, indicating challenges in profitability, growth, and valuation, while insider activity shows a selling trend of $0.8 million in shares. Investors are advised to weigh these factors carefully.
Truist Raises Price Target on Beta Bionics to $22 From $18, Keeps Buy Rating
Truist Securities has increased its price target for Beta Bionics (NASDAQ: BBLN) to $22 from $18, while reiterating a "Buy" rating on the stock. This adjustment suggests a positive outlook on the company's financial prospects and stock performance.
If You Invested $1,000 in Beta Bionics, Inc. (BBNX)
This article analyzes the historical performance of Beta Bionics, Inc. (BBNX) stock, specifically calculating the return on a hypothetical $1,000 investment over different periods. It highlights that a $1,000 investment one year ago would now be worth $1,346, a 34.6% increase. The article also provides detailed information about Beta Bionics, Inc.'s business, its iLet Bionic Pancreas product, commercialization strategies, and financial reporting.
Truist Raises Price Target on Beta Bionics to $22 From $18, Keeps Buy Rating
Truist has increased its price target for Beta Bionics (NASDAQ: BBNX) to $22 from $18, while maintaining a Buy rating on the stock. This adjustment reflects continued confidence in the medical device company, known for its iLet Bionic Pancreas. The article also notes recent news regarding Beta Bionics' product recalls and its commercialization timelines for other devices.
Price to book forward of Beta Bionics, Inc. – NASDAQ:BBNX
This article provides financial information for Beta Bionics, Inc. (NASDAQ: BBNX) on TradingView, specifically focusing on its "Price to book forward" metric. It indicates that the markets are closed with no trades and gives details on the data sources used. The content seems to be a financial data page rather than a traditional article.
ETFs Investing in Beta Bionics, Inc. Stocks
This article lists several ETFs that invest in Beta Bionics, Inc. (BBNX) stocks, providing details such as market value, weight, issuer, expense ratio, and performance. The ETFs offer investors diversified exposure to the medical technology sector and small-cap companies, among others. The information aims to help investors identify funds that include BBNX, making stock investing more accessible with lower risk.
Price to earnings forward of Beta Bionics, Inc. – NASDAQ:BBNX
This article focuses on the "Price to earnings forward" financial metric for Beta Bionics, Inc. (NASDAQ: BBNX) as reported by TradingView. The page displays the company's stock information, along with navigation to various financial and community features on the TradingView platform.
Enterprise value to EBITDA forward of Beta Bionics, Inc. – NASDAQ:BBNX
This article provides financial data for Beta Bionics, Inc. (NASDAQ: BBNX), specifically focusing on its enterprise value to EBITDA forward metric. The content appears to be a financial data snippet from TradingView, indicating the period, value, and change for this specific financial ratio for the company.
Beta Bionics CFO Stephen Feider sells $170k of BBNX stock
Stephen Feider, CFO of Beta Bionics (NASDAQ:BBNX), sold 10,000 shares of company stock for a total of approximately $170,387 across two transactions in late June. These sales were made under a Rule 10b5-1 trading plan and occurred concurrently with the exercise of employee stock options for the same number of shares. The company's stock is currently trading at $16.77, and recent reports indicate Beta Bionics surpassed Q1 revenue estimates and raised its guidance.
CFO trades 10,000 Beta Bionics (BBNX) shares under Rule 10b5-1 plan
Beta Bionics' Chief Financial Officer, Stephen Feider, executed an amended insider transaction, exercising options for 10,000 shares and subsequently selling them on the open market. The sales, conducted on June 26 and June 29, 2026, were made under a pre-arranged Rule 10b5-1 trading plan. This amendment clarifies the number of shares from a previous option exercise and updates his beneficial ownership, which now stands at 166,053 shares directly held.
Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
Beta Bionics, Inc. announced its plan to release second quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will host a conference call and webcast on the same day at 4:30 pm Eastern Time to discuss its performance. The webcast link and dial-in details will be available on the company's investor relations website.
Beta Bionics sets July 29 call for Q2 2026 results
Beta Bionics (Nasdaq: BBNX) announced it will release its second quarter 2026 financial results after market close on Wednesday, July 29, 2026. Management will host a conference call and webcast on the same day at 4:30 pm ET to discuss the quarterly performance. The announcement caused a positive market reaction, with BBNX shares gaining 6.57%.
Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
Beta Bionics, Inc. (Nasdaq: BBNX) announced it will release its second quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will host a conference call and webcast on the same day at 4:30 pm Eastern Time to discuss its performance. The webcast link will be available on the company's investor relations website.
Beta Bionics to announce Q2 2026 financial results on July 29
Beta Bionics will release its second-quarter 2026 financial results after market close on Wednesday, July 29, 2026. The medical device company, known for its iLet Bionic Pancreas, will host a conference call and webcast at 4:30 pm ET on the same day to discuss its performance. The webcast will be available on the "Investors—Events & Presentations" section of their website for replay.
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
Johnson Fistel, PLLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) for potential securities law violations, focusing on whether the company made misleading statements regarding its growth and operating metrics. This investigation comes after Beta Bionics reported Q4 2025 new patient starts that fell below analyst expectations and showed a significant deceleration in growth. Investors who suffered losses in Beta Bionics securities are encouraged to contact Johnson Fistel to explore their legal rights.
Beta Bionics (BBNX) CFO sells 10,000 shares under 10b5-1 trading plan
Beta Bionics, Inc. (BBNX) Chief Financial Officer Stephen Feider sold 10,000 shares of common stock in open-market transactions between June 26 and June 29, 2026, at weighted average prices around $17.04. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in May 2025, following the exercise of stock options for 9,878 shares at $5.10 each. Feider retained a significant equity position, directly holding 165,931 shares after these transactions.
